Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics.
Veligrotug, an anti-insulin-like growth factor-1 receptor antibody delivered intravenously, was assigned a Prescription Drug User Fee Act date of June 30, 2026, with priority review shortening the biologics license application target review timeline from 10 months to 6 months. The BLA was supported by positive data from the phase 3 THRIVE and THRIVE2 clinical trials, which met all primary and secondary endpoints.
According to the release, veligrotug